Novo Nordisk announces changes in Executive Management
Novo Nordisk today announced the following changes in Executive Management. After a distinguished career of 28 years with ...
Nature1d
Obesity-drug pioneers and 13,508 physicists win US$3-million Breakthrough Prizes
Advances recognized by science’s most lucrative awards include Large Hadron Collider experiments and groundbreaking ...
Novo Nordisk shares post the biggest monthly decline since 2002
Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...
Taiwan News7d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Based on data from the SOUL clinical trial, Novo Nordisk submitted a label extension application for Rybelsus ®, which has been accepted for review by the European Medicines Agency (EMA) and the US ...
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors ...
Novo Nordisk's head of commercial strategy Camilla Sylvest steps down
Novo Nordisk (NVO) said Thursday Camilla Sylvest has decided to leave the company, after a distinguished career of 28 years ...
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
The issuer is solely responsible for the content of this announcement.
BioWorld12d
In a $2B deal, Novo licenses obesity drug from China’s United Bio
Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors ...
Pharmabiz4d
Novo Nordisk presents positive results from SOUL cardiovascular outcomes trial of Rybelsus at ACC’s annual scientific session
Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...